Fig. 1From: A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomasTumor response. A Best change from baseline in target lesion. B Percentage change from baseline in target lesion tumor burden over time. C Time to response and duration of responseBack to article page